Wharton Business Group’s Teva Pharmaceuticals TEVA Stock Holding History

Wharton Business Group’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q3	–	Sell	-9,938	Closed	-$499K	–	125
2016 Q2	$499K	Sell	9,938 -309	-3%	-$16.4K	0.06%	95
2016 Q1	$548K	Hold	10,247	–	–	0.06%	95
2015 Q4	$673K	Hold	10,247	–	–	0.07%	92
2015 Q3	$579K	Sell	10,247 -2,625	-20%	-$170K	0.06%	95
2015 Q2	$761	Sell	12,872 -400	-3%	-$24.7K	0.05%	96
2015 Q1	$827K	Sell	13,272 -917	-6%	-$53.3K	0.07%	103
2014 Q4	$816K	Hold	14,189	–	–	0.07%	99
2014 Q3	$763K	Buy	14,189 +1,095	+8%	+$58K	0.07%	105
2014 Q2	$686K	Sell	13,094 -1,735	-12%	-$88.7K	0.08%	108
2014 Q1	$784K	Hold	14,829	–	–	0.06%	117
2013 Q4	$594K	Hold	14,829	–	–	0.05%	121
2013 Q3	$560K	Hold	14,829	–	–	0.05%	119
2013 Q2	$581K	Buy	+14,829	New	+$577K	0.05%	118

Other funds holding TEVA

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Barrow, Hanley, Mewhinney & Strauss Dallas, Texas $30.5B AUM 29.95% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Lazard Asset Management New York $60.8B AUM 22.47% 1-Year Est. Return

WRF

Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Wharton Business Group's TEVA Position: Q3 2016 in Review

Wharton Business Group sold out of Teva Pharmaceuticals (TEVA) in Q3 2016, closing a stake of 9,938 shares — an estimated $499K sold.

Wharton Business Group first reported a position in TEVA in Q2 2013 and held it in 13 quarters. The position peaked at $827K in Q1 2015. 795 funds tracked by Wall St. Rank hold TEVA as of Q3 2016.

Wharton Business Group reported no remaining Teva Pharmaceuticals position as of Q3 2016 after selling out during the quarter.
Wharton Business Group sold 9,938 Teva Pharmaceuticals shares in Q3 2016, an estimated $499K.
Wharton Business Group first reported a position in Teva Pharmaceuticals in Q2 2013 and held it in 13 quarters.
Wharton Business Group's Teva Pharmaceuticals position peaked at $827K in Q1 2015.
795 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q3 2016.

Based on Wharton Business Group's 13F filing for Q3 2016, filed 10 Nov 2016.